We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+5.49%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$607M
AUM Growth
+$64.8M
Cap. Flow
+$73M
Cap. Flow %
12.03%
Top 10 Hldgs %
61%
Holding
61
New
22
Increased
13
Reduced
4
Closed
21

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$22M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$19.8M
3
CORT icon
Corcept Therapeutics
CORT
+$19.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$17M
5
AZN icon
AstraZeneca
AZN
+$16.8M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$19.5M
2
ABLX
Ablynx NV
ABLX
+$15.9M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11M
4
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$9.16M
5
VTRS icon
Viatris
VTRS
+$8.92M

Sector Composition

Rank Sector Weight
1 Healthcare 62.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
51
TG Therapeutics
TGTX
$7.96B
– –
-30,000
Closed -$246K
TXMD icon
52
TherapeuticsMD
TXMD
$23.5M
– –
-10,567
Closed -$3.19M
VTGN icon
53
VistaGen Therapeutics
VTGN
$9.89M
– –
-4,604
Closed -$154K
MRNS
54
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-231,332
Closed -$7.55M
SPPI
55
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-259,300
Closed -$4.91M
OTIC
56
DELISTED
Otonomy, Inc.
OTIC
– –
-602,748
Closed -$3.35M
FLXN
57
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-466,500
Closed -$11.7M
ALXN
58
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-72,400
Closed -$8.66M
TSRO
59
PUT
DELISTED
TESARO, Inc.
TSRO
– –
-50,000
Closed -$4.14M
ABLX
60
DELISTED
Ablynx NV
ABLX
– –
-637,884
Closed -$15.9M
SCMP
61
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-510,486
Closed -$9.16M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Nexthera Capital held 61 positions worth $607M, up 12% from $542M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Nexthera Capital deployed $73M of net new capital in Q1 2018, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Bristol-Myers Squibb: 342,399 shares worth $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 48% a quarter earlier.

On the sell side, the largest reduction was Viatris, an estimated $8.92M trimmed.

  • Nexthera Capital's largest Q1 2018 buy was Bristol-Myers Squibb: 342,399 shares worth $21.7M.
  • Nexthera Capital added most to Immunomedics Inc in Q1 2018, an estimated $11.1M increase.
  • Nexthera Capital's biggest Q1 2018 reduction was Viatris, cutting an estimated $8.92M.
  • Nexthera Capital fully exited Merck in Q1 2018, selling an estimated $19.5M.
  • Nexthera Capital's ten largest holdings make up 61% of its $607M portfolio in Q1 2018.
  • Nexthera Capital opened 22 new positions and closed 21 in Q1 2018.
  • Nexthera Capital's portfolio value rose 12% quarter-over-quarter to $607M.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.